Sec. 30216. Expanding investment by United States International Development Finance Corporation for vaccine manufacturing, distribution, storage, and delivery
258 words·~1 min read·
/bill/117/hr/4521/eh/section-30216A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The Development Finance Corporation is authorized to provide financing to entities in India and in other less developed countries to increase vaccine manufacturing, distribution, storage, and delivery capacity for the following purposes: Manufacturing Stringent Regulatory Authorization
(SRA)or World Health Organization
(WHO)Emergency Use Listing COVID–19 vaccines. Manufacturing SRA or WHO Emergency Use Listing therapeutics used to treat symptoms related to COVID–19. Manufacturing critical medical supplies needed for preventing, detecting and treating COVID–19, including ventilators, personal protective equipment, oxygen, diagnostics, auto-disable syringes, therapeutics and vaccines. Enhancing the cold chain necessary for the production, delivery, storage, and distribution of vaccines. Not later than 180 days after the date of the enactment of this Act, the Chief Executive Officer of the Development Finance Corporation, in coordination with the Secretary of State, shall provide a report to the appropriate congressional committees— outlining the countries where DFC financing could be most impactful for vaccine manufacturing, distribution, storage, and delivery and to achieve the goal of manufacturing, distributing, and delivering 1 billion COVID–19 vaccines by 2022; including a detailed explanation of the United States and partner country interests served by the United States providing support to such projects; including a detailed description of any support provided by other United States allies and partners to expand the initiatives outlined in subsection (a); and including a detailed description of any support provided by the People’s Republic of China in support of the initiatives outlined in subsection (a). The report required by subsection
(b)shall be submitted in unclassified form with a classified annex if necessary.